Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Cardiovascular Systems was 66.90% per year. The lowest was -62.10% per year. And the median was 12.80% per year.
Competitive Comparison of Cardiovascular Systems's 5-Year EBITDA Growth Rate
For the Medical Devices subindustry, Cardiovascular Systems's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cardiovascular Systems's 5-Year EBITDA Growth Rate Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Cardiovascular Systems's 5-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Cardiovascular Systems's 5-Year EBITDA Growth Rate falls into.
Cardiovascular Systems 5-Year EBITDA Growth Rate Calculation
This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
Cardiovascular Systems (NAS:CSII) 5-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.
Cardiovascular Systems 5-Year EBITDA Growth Rate Related Terms
Thank you for viewing the detailed overview of Cardiovascular Systems's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.
Cardiovascular Systems (Cardiovascular Systems) Business Description
Cardiovascular Systems Inc is a medical technology company focused on patients with peripheral and coronary artery diseases. Its peripheral artery disease systems are catheter-based platforms used to treat plaque in leg arteries above and below the knee. The firm's orbital atherectomy systems are used in peripheral and coronary commercial applications. Its OAS products include the Diamondback 360 Peripheral and Stealth 360 systems. Sales of Peripheral OAS contribute the majority of revenue. Cardiovascular systems generate the vast majority of its revenue in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
CSII has been successfully added to your